Articles On ImpediMed (ASX:IPD)

Wall Street bounces back All major indices in the US have bounced back, after falling the previous day. Both the Dow Jones and S&P 500 rose by 0.93%, while tech heavy NASDAQ also rose by 1.19%. It was a broad-based increase across all s...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

ImpediMed (ASX.IPD) has announced the publication of a peer-reviewed manuscript demonstrating the clinical utility of its SOZO device in monitoring heart failure patients.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The health...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

The Impedimed Ltd (ASX: IPD) share price shot higher this morning, up 5% in morning trade.  This came after the ASX medical technology company reported a significant uptick in the number of tests conducted with one of its leading medical d...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((3PL)) - 3P Learning ((ALD)) - Ampol ((AD8)) - Audinate Group ((BIN)) - Bingo Industries ((BSL)) - BlueScope Steel ((BKG)) - Booktopia Group ((CNU)) - Chorus ((CGC)) - Co...

The Impedimed Limited (ASX: IPD) share price will be closely watched by investors this morning. This comes after the medical technology company announced that it has concluded its long-running Prevent trial. At the closing bell yesterday,...

Summary ImpediMed Limited (ASX:IPD) has secured the Health Information Trust Alliance Certification (HITRUST). HITRUST sets the global standard for safeguarding information. ImpediMed’s goal is to make continuous improvements in safeg...

Summary ImpediMed Limited (ASX:IPD) is an emerging contemporary medical technology company that produces a family of FDA cleared and CE Marked medical devices. The Company uses bioimpedance spectroscopy (BIS) technologies to generate p...

Summary ImpediMed Limited (ASX:IPD) has recently announced the publication of meta-analysis. The meta-analysis demonstrates effectiveness of ImpediMed's BIS L-Dex® technology in reducing rates of long-term breast cancer-related lymphoe...

The Impedimed Limited (ASX: IPD) share price lifted this morning on positive results from a significant cancer screening study. The results show that its bio-impedance spectroscopy (BIS) technology is more effective in screening and detect...

Summary ImpediMed Limited (ASX:IPD) has announced the first order for its SOZO® Digital Health Platform. Phoenix Healthcare Network has initially purchased five SOZO®® units, with implementation likely to commence in early FY21. SO...

“Program expansion with existing customers is a critical aspect of our growth strategy in the coming quarters”, says Richard Carreon, Managing Director and CEO of ImpediMed Limited. In a significant partnership update with NSW Health, ...

World leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies, ImpediMed Limited (ASX:IPD) has met a major milestone. The globally renowned pharmaceutical company, AstraZeneca has selec...

The Impedimed Limited (ASX: IPD) share price rocketed by 13.41% today to close the day’s trade at 9.3 cents per share. This came after the company announced that its Sozo medical device has been selected by AstraZeneca for use in a phase 2...

AstraZeneca has entered an agreement with Australian medical technology company ImpediMed under which it will use one of its digital health platforms for a clinical trial.

Medical technology company ImpediMed (ASX: IPD) unveiled a timely contract valued at over $2 million for its SOZO digital health platform, which paves the way for it to be used in a clinical trial by global biopharmaceutical giant AstraZene...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Earnings s...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With repor...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Victoria h...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   This week’s big themes The ca...

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

The announcement lands just before markets open, ‘the TGA has approved our device’; the buy orders begin to pile up and the pre-open share price begins to surge. But while a nod from Australia’s drug and device regulator, the Therapeutic Go...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Morgans Senior Analyst Scott Power updates the network with information on 3 companies: Volpara (ASX:VHT), Impedimed (ASX:IPD) and Micro-X (ASX:MX1).

ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), has received the first order of 16 units under...

Medical devices company ImpediMed was in the market for fresh equity on Monday night. 

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

The National Comprehensive Care Network (NCCN) has updated its Guidelines for Breast Cancer regarding early detection and diagnosis of lymphoedema, which ImpediMed (ASX: IPD) hopes to take advantage of with its non-invasive bioimpedance spe...

ImpediMed (IPD) reports that the national comprehensive care network has recommended that healthcare providers take a pre-treatment baseline measurement The measurement will be for patients with lymphoedema risk factors The update follows...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

ImpediMed (IPD) has reported increased revenue for the December 2019 quarter Total revenue is up 63 per cent, while revenue for its SOZO device is skyrocketed 216 per cent SOZO helps clinicians provide individualised care to patients expe...

ImpediMed’s (ASX:IPD) December quarter report includes the word ‘up’ eight times and the word ‘down’ not at all, and yet the company’s shares dropped nearly 17 per cent at market open. The stock fell from 17c to 14c. ImpediMed expects to on...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

The powerful US Food and Drug Administration (FDA) has cleared a body scanner to check whether a person has protein calorie malnutrition, a risk of the highly popular Keto diet. Impedimed’s (ASX:IPD) scanner SOZO can tell how much and where...

The ‘software as a service’ (SAAS) business model has taken off in the computer software sector over the past few years. Now, the same concept is gaining traction in medtech. Take Volpara Health Technologies (ASX:VHT), a breast imaging soft...

Australia has an excellent medical research, and health care infrastructure, as a result the Australian health care system has been the global benchmark for decades. In Australia, the health care industry is backed by the national and state...

Australian Stock Exchange (ASX), a leading stock exchange houses over 2,185 listed entities in its premises. Investors have a wide variety of businesses to choose from, among even wider industries of the country. In this article, we focus o...